Results 81 to 90 of about 106,775 (245)

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea

Obesity Science & Practice
Background and Aim Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are well‐established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA).
Bei‐Bei Qian, Yu‐Jie Huang, Cai‐Feng Yan, Shang‐Yong Feng, Dun‐Min She   +4 more
doaj   +1 more source

A neuronal relay mediates a nutrient responsive gut/fat body axis regulating energy homeostasis in adult Drosophila [PDF]

, 2019
The control of systemic metabolic homeostasis involves complex inter-tissue programs that coordinate energy production, storage, and consumption, to maintain organismal fitness upon environmental challenges.
Bauer, Christin, Cordero, Julia B., Kruspig, Bjorn, Maddocks, Oliver D.K., Murphy, Daniel J., Scopelliti, Alessandro, Vidal, Marcos, Yu, Yachuan, Zhang, Tong   +8 more
core   +1 more source

Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists [PDF]

, 2019
Dimitrios Patoulias, Maria‐Styliani Kalogirou, Konstantinos Stavropoulos, Κonstantinos Imprialos, Michael Doumas   +4 more
openalex   +1 more source

Physiology and pharmacology of glucagon-like peptide-1 receptor

Фармация и фармакология (Пятигорск)
Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks.
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, V. I. Petrov, A. V. Strygin, K. N. Koryanova, Yu. V. Gorbunova, Yu. A. Kolosov, O. V. Ivanova, E. V. Pavlova, M. A. Dzhavakhyan, A. V. Zaborovsky, V. B. Saparova, I. E. Makarenko, R. I. Drai, A. N. Chumachenko   +15 more
doaj   +1 more source

Decision letter for "Cardiovascular risk profiles: A cross‐sectional study evaluating the generalisability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials Rewind , Leader and Sustain ‐6 to the real‐world type 2 diabetes population in the UK"

, 2021

openalex   +1 more source

Effect of Lixisenatide (Short-acting Glucagon-Like Peptide 1 Receptor Agonist) as an Add-on to Insulin in Lowering HbA1C among Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [PDF]

, 2023
Ashwaq Ali Abusalem, Ahmad Raja Albalawi
openalex   +1 more source

Unraveling the obesity–asthma link: A new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease

Journal of International Medical Research
The global prevalence of obesity and asthma has escalated in parallel over recent decades, presenting an intertwined public health crisis. Obesity not only increases the risk of asthma development but also complicates its clinical course by altering ...
Francesco Menzella, Marcello Cottini, Rory Chan   +2 more
doaj   +1 more source

The Effects of Glucagon-Like Peptide-1 Receptor Agonists of Liraglutide on Bone Turnover Makers Among Type 2 Diabetes Mellitus Patients: A Meta-Analysis of Randomized Controlled Trials

, 2022
Jing-yi Kang, Shanshan Lei, Jintao Guan
openalex   +1 more source

Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain

Neural Regeneration Research
The glucagon-like peptide 1 is a pleiotropic hormone that has potent insulinotropic effects and is key in treating metabolic diseases such as diabetes and obesity. Glucagon-like peptide 1 exerts its effects by activating a membrane receptor identified in
Yolanda Diz-Chaves, Zainab Maastor, Carlos Spuch, José Antonio Lamas, Lucas C González-Matías, Federico Mallo   +5 more
doaj   +1 more source

Clinical pharmacology of glucagon-like peptide-1 receptor agonists

Hormones, 2018
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important asset in the armamentarium for the treatment of type 2 diabetes mellitus (type 2 DM). Incretin failure is a critical etiopathogenetic feature of type 2 DM, which, if reversed, results in improved glycaemic control.
Sfairopoulos, D., Liatis, S., Tigas, S., Liberopoulos, E.   +3 more
openaire   +3 more sources